Evidence map›Paper›PMID 38034487›Full record

ArticleOncology letters2024

Clinicopathological and molecular pathological characteristics in tamoxifen‑related endometrial cancer.

Harumi Saeki, Yoshiya Horimoto, May Thinzar Hlaing, Yuan Men, Lu Rong, Yumiko Ishizuka, Toshitaka Uomori, Emiko Yoshida, Yasuhisa Terao, Atsushi Arakawa and 2 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Harumi SaekiDepartment of Human Pathology, Juntendo University Faculty of Medicine, Tokyo 113-0033, Japan.
Yoshiya HorimotoDepartment of Human Pathology, Juntendo University Faculty of Medicine, Tokyo 113-0033, Japan.
May Thinzar HlaingDepartment of Breast Oncology, Juntendo University Faculty of Medicine, Tokyo 113-0033, Japan.
Yuan MenDepartment of Human Pathology, Juntendo University Graduate School of Medicine, Tokyo 113-0033, Japan.
Lu RongDepartment of Human Pathology, Juntendo University Graduate School of Medicine, Tokyo 113-0033, Japan.
Yumiko IshizukaDepartment of Breast Oncology, Juntendo University Faculty of Medicine, Tokyo 113-0033, Japan.
Toshitaka UomoriDepartment of Breast Oncology, Juntendo University Faculty of Medicine, Tokyo 113-0033, Japan.
Emiko YoshidaDepartment of Obstetrics and Gynecology, Juntendo University Faculty of Medicine, Tokyo 113-0033, Japan.
Yasuhisa TeraoDepartment of Obstetrics and Gynecology, Juntendo University Faculty of Medicine, Tokyo 113-0033, Japan.
Atsushi ArakawaDepartment of Human Pathology, Juntendo University Faculty of Medicine, Tokyo 113-0033, Japan.
Tsuyoshi SaitoDepartment of Human Pathology, Juntendo University Faculty of Medicine, Tokyo 113-0033, Japan.
Takashi YaoDepartment of Human Pathology, Juntendo University Faculty of Medicine, Tokyo 113-0033, Japan.
Juntendo University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tamoxifen (TAM), a selective estrogen receptor modulator, is often used for long-term adjuvant endocrine therapy in patients with hormone receptor-positive breast cancer. TAM is known to increase the risk of endometrial cancer (EC); however, the mechanism has not yet been fully elucidated. Therefore, molecular genetic analysis of EC following TAM administration (TAM-related EC) was conducted. A total of 10 samples of TAM-related EC and 20 sporadic EC samples (as controls) were analyzed. Copy number variation analysis was conducted, microsatellite instability (MSI) status was assessed, and mismatch repair (MMR) protein expression was examined immunohistochemically. Copy number variation analysis revealed that

Indexed as

breast cancercopy number variationendometrial cancermicrosatellite instabilityreceptor protein-tyrosine kinasestamoxifen

Identifiers

PMID38034487
PMCPMC10688500
OpenAlexW4388538388

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.